Cialis FDA Approval History: Every Indication, Label Change, and Safety Update

The Original 2003 FDA Approval for Erectile Dysfunction

Tadalafil received FDA approval on November 21, 2003, under the brand name Cialis, making it the second oral PDE5 inhibitor approved in the United States after sildenafil (Viagra, 1998) and the first with a half-life long enough to allow a 36-hour window of efficacy. The original New Drug Application (NDA 021368) was submitted by ICOS Corporation, which later merged with Eli Lilly in 2007.

The Key Trial Data That Supported Approval

The clinical package that convinced the FDA rested on multiple randomized, placebo-controlled studies. Brock et al. (2002, J Urol, N=179) demonstrated that tadalafil 20 mg produced statistically significant improvements in erectile function domain scores and successful intercourse rates compared with placebo, with a P<0.001 for the primary endpoint [1]. Pooled analyses across the development program showed that tadalafil 20 mg enabled successful intercourse attempts in approximately 75% of men, compared with roughly 32% on placebo [2].

Initial Approved Doses and Labeling

At launch, the FDA approved three as-needed doses: 5 mg, 10 mg, and 20 mg. The label specified that tadalafil should be taken at least 30 minutes before anticipated sexual activity and that no more than one dose per 24 hours should be used. The starting recommended dose was 10 mg, with titration up or down based on efficacy and tolerability.

The original label carried a boxed warning about hypotension when combined with nitrates, reflecting the mechanism by which PDE5 inhibitors potentiate nitric-oxide-mediated vasodilation [3].

Why the 36-Hour Window Mattered Clinically

Sildenafil's half-life runs 3 to 5 hours. Tadalafil's runs approximately 17.5 hours, producing a duration of action that clinical trial participants described as allowing sexual activity for up to 36 hours post-dose. That property drove the drug's marketing as "the weekend pill," but it also introduced a longer window of potential drug interactions, a fact the FDA addressed in labeling by requiring explicit nitrate interaction language.

Once-Daily Dosing Approval (2008)

In 2008, the FDA approved tadalafil 2.5 mg and 5 mg for once-daily use in erectile dysfunction, the first PDE5 inhibitor to receive such an indication in the US. The rationale was that once-daily dosing maintains steady-state plasma concentrations, eliminating the need to time doses relative to sexual activity [4].

Supporting Pharmacokinetics

At 5 mg once daily, tadalafil reaches steady-state plasma concentrations within 5 days. The coefficient of variation for AUC at steady state is approximately 35%, which the FDA reviewers considered acceptable for a drug with a relatively flat dose-response curve in the therapeutic range [4].

Label Language on Once-Daily Use

The prescribing information for once-daily tadalafil specifies that the dose should be taken at approximately the same time each day, without regard to timing of sexual activity. The label also notes that no dose adjustment is required in patients with mild-to-moderate hepatic impairment, but that tadalafil is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) [3].

Benign Prostatic Hyperplasia Indication (2011)

On October 6, 2011, the FDA approved tadalafil 5 mg once daily for the signs and symptoms of benign prostatic hyperplasia (BPH) and for the simultaneous treatment of BPH and ED. This made tadalafil the only PDE5 inhibitor approved for BPH, and the approval was supported by the LVHJ-1 program of four key 12-week, randomized, placebo-controlled trials [5].

LVHJ-1 Trial Findings

Across the BPH program, tadalafil 5 mg once daily reduced total International Prostate Symptom Score (IPSS) by a mean of 3.8 points from baseline compared with 1.7 points for placebo, a difference of 2.1 points (P<0.001) [5]. The FDA reviewers noted that while alpha-blockers produce larger IPSS reductions (typically 4 to 6 points), tadalafil offered an option for men who preferred a single agent addressing both BPH and ED.

Combination BPH-Plus-ED Labeling

The 2011 label update explicitly states: "CIALIS is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). CIALIS is indicated for the simultaneous treatment of erectile dysfunction and the signs and symptoms of BPH (ED/BPH)" [3]. This language remains in the current prescribing information as of the most recent FDA label revision.

The table below summarizes how tadalafil's approved indications and doses have expanded across its US regulatory history.

| Year | Regulatory Action | Dose(s) | Brand | |------|------------------|---------|-------| | 2003 | ED, as-needed | 5, 10, 20 mg | Cialis | | 2008 | ED, once-daily | 2.5, 5 mg | Cialis | | 2009 | PAH | 20 mg (Adcirca) | Adcirca | | 2011 | BPH; ED + BPH | 5 mg once-daily | Cialis | | 2014 | Pediatric PAH labeling | Weight-based | Adcirca | | 2018 | Generic tadalafil approved | All doses | Multiple |

Pulmonary Arterial Hypertension (Adcirca, 2009)

The FDA approved tadalafil 20 mg under the brand name Adcirca on May 22, 2009, for pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise ability. The approved dose, 40 mg once daily (two 20 mg tablets), is distinct from the ED and BPH doses [6].

PHIRST Trial Data

The PHIRST trial (N=405, randomized, double-blind, placebo-controlled, 16 weeks) showed that tadalafil 40 mg once daily increased the 6-minute walk distance by a mean of 33 meters compared with placebo (P<0.01) [6]. Patients on background bosentan therapy showed a smaller but still positive effect. The FDA reviewers cited these data as sufficient for approval given the seriousness of PAH and the limited treatment options available at the time.

Pediatric PAH Labeling Update (2014)

In 2014, the FDA updated Adcirca labeling to include pharmacokinetic and dosing data in pediatric patients weighing at least 20 kg, based on a population PK model. The pediatric dose is weight-based: 20 mg once daily for patients 20 to 40 kg, and 40 mg once daily for patients above 40 kg [7].

Generic Tadalafil Enters the US Market (2018)

Eli Lilly's market exclusivity for tadalafil expired in September 2018. The FDA approved the first generic tadalafil ANDAs (Abbreviated New Drug Applications) at that time, and multiple manufacturers now market generic tadalafil in the 2.5 mg, 5 mg, 10 mg, and 20 mg tablet strengths [8].

Generic entry reduced the out-of-pocket cost of tadalafil substantially, from approximately $400 per month for brand-name Cialis to under $20 per month for generic 5 mg tablets at many US pharmacies by 2020 [8].

FDA Bioequivalence Standards for Generic Tadalafil

Each generic ANDA must demonstrate bioequivalence to the reference listed drug using a standard 90% confidence interval for AUC and Cmax that falls within 80% to 125% of the brand. The FDA's Orange Book lists tadalafil as therapeutically equivalent (TE code "AB") to Cialis for all approved strengths [8].

Current FDA Label: Key Safety Requirements

The current tadalafil prescribing information (revised most recently in 2023) contains several mandatory safety communications that prescribers must convey to patients [3].

Nitrate Contraindication

The label states: "Administration of CIALIS to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated" [3]. This contraindication reflects the risk of severe hypotension. Nitrate forms covered include sublingual nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and recreational nitrites (poppers).

Alpha-Blocker Interaction

Tadalafil can potentiate the blood-pressure-lowering effect of alpha-blockers. The label permits concurrent use only when the patient is hemodynamically stable on alpha-blocker therapy, and it recommends initiating tadalafil at the lowest available dose (2.5 mg once-daily or 5 mg as-needed) [3].

CYP3A4 Drug Interactions

Tadalafil is metabolized primarily by CYP3A4. The label requires that the dose be limited to 10 mg no more than once every 72 hours in patients taking strong CYP3A4 inhibitors such as ketoconazole, ritonavir, or clarithromycin [3]. Patients on rifampin or other strong CYP3A4 inducers may experience substantially reduced tadalafil plasma levels, and the clinical consequence should be discussed during prescribing.

Vision and Hearing Warnings

Post-marketing reports of non-arteritic anterior ischemic optic neuropathy (NAION) led the FDA to add a warning in 2005, recommending that patients who experience sudden vision loss discontinue tadalafil and seek immediate evaluation [9]. A similar warning for sudden hearing loss was added in 2007 after spontaneous adverse event reports to MedWatch [9].

Priapism Warning

The label warns that prolonged erections (greater than 4 hours) and priapism (greater than 6 hours) have been reported with PDE5 inhibitors including tadalafil. Patients should be instructed to seek emergency care if an erection lasts more than 4 hours, as irreversible penile tissue damage may occur [3].

Post-Market Safety Surveillance and Label Revisions

The FDA's post-market surveillance of tadalafil has generated several label revisions since the 2003 approval, reflecting data from MedWatch spontaneous reports, the FDA Sentinel System, and published pharmacovigilance studies.

2005 NAION Warning Addition

After reports of sudden monocular vision loss associated with PDE5 inhibitor use, the FDA required all three approved PDE5 inhibitors at the time to update their labels in July 2005. The warning notes that many affected patients had anatomical or vascular risk factors for NAION (a "crowded disc," hypertension, diabetes), but a causal relationship could not be excluded [9].

2007 Hearing Loss Warning

The FDA issued a safety communication in October 2007 and required label updates for tadalafil, sildenafil, and vardenafil to warn of rare but serious sudden hearing loss [9]. The mechanism remains unclear; the FDA reviewed 29 MedWatch cases at the time of the label change, acknowledging that the absolute risk appeared low.

Cardiovascular Risk Context

A 2014 meta-analysis of tadalafil in cardiovascular outcomes (published in JAMA Internal Medicine, N=7,969 across 42 trials) found no significant increase in major adverse cardiovascular events compared with placebo in men with ED, though the authors noted that most trial durations were under 6 months and longer-term data were limited [10]. The current FDA label allows tadalafil use in stable cardiovascular disease but notes that sexual activity itself carries some cardiac risk, referencing the Princeton Consensus guidelines for cardiovascular risk stratification before initiating ED therapy [3].

Regulatory Pathway: How Tadalafil Was Reviewed

The FDA reviewed tadalafil under a standard (non-priority) review, with a 12-month review clock for the original NDA. Priority review, which shortens the clock to 6 months, is reserved for drugs that offer a major advance over available therapy; because sildenafil was already on the market, tadalafil did not qualify [11].

NDA 021368 and the Role of ICOS Corporation

ICOS Corporation, based in Bothell, Washington, developed tadalafil through Phase 1, 2, and 3 before filing NDA 021368. The compound was discovered during a research collaboration between ICOS and Eli Lilly. After the 2003 approval, Eli Lilly acquired ICOS in January 2007 for approximately $2.1 billion, consolidating the commercial rights [11].

Supplemental NDAs for Each New Indication

Each indication expansion (once-daily ED in 2008, BPH in 2011) required a supplemental NDA (sNDA) with new clinical data. The FDA's Division of Urology, Obstetrics, and Gynecology (now within the Office of Cardiology, Hematology, Endocrinology, and Nephrology) reviewed these submissions. Each sNDA reset the patent exclusivity clock for the new indication, contributing to Eli Lilly's ability to maintain brand exclusivity until 2018 [11].

What Prescribers and Patients Should Know About the Current Label

The FDA-approved prescribing information for tadalafil as of 2023 communicates several practical points that affect clinical use [3].

Renal impairment requires dose adjustment: for creatinine clearance 31 to 50 mL/min, the maximum as-needed dose is 5 mg per 72 hours; for creatinine clearance below 30 mL/min, tadalafil is not recommended for once-daily use and the as-needed dose should not exceed 5 mg per 72 hours [3].

The label also confirms that tadalafil has no effect on sperm motility or morphology at the 10 mg and 20 mg doses studied in a Phase 1 trial of healthy male volunteers, a point relevant to men of reproductive age [3].

Alcohol interaction is addressed in the label's pharmacodynamic section: five units of alcohol did not substantially alter tadalafil's cardiovascular effects in a clinical pharmacology study, though both alcohol and tadalafil have vasodilatory properties and the combination may increase the risk of orthostatic symptoms [3].

The FDA label states: "Patients should be advised that tadalafil offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV), should be considered" [3]. This language is unchanged since the 2003 approval.